SEATTLE--ZymoGenetics Inc. has begun construction of a new 46,000-square-foot, $12 million R&D facility located adjacent to the company's headquarters. The new building will later be expanded to 78,500 square feet.
ZymoGenetics is the North American Health Care Drug Discovery unit of the Danish pharmaceutical company Novo Nordisk A/S. It employs over 250 staff in the pursuit of bioinformatics-driven discovery of therapeutic proteins.